Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Telix Pharmaceuticals's accounts receivables for the quarter that ended in Dec. 2025 was A$194 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Telix Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2025 was 57.03.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Telix Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was A$-2.18.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Telix Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Telix Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:
Telix Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Telix Pharmaceuticals Accounts Receivable Related Terms
Telix Pharmaceuticals Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of A$194 Mil mean?
Telix Pharmaceuticals (ASX:TLX) has a Accounts Receivable of A$194 Mil as of Dec. 2025. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Telix Pharmaceuticals and its competitors.
Is Telix Pharmaceuticals' Accounts Receivable too high?
Telix Pharmaceuticals' current Accounts Receivable is A$194 Mil. Overall, Telix Pharmaceuticals has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Accounts Receivable compare to VRTX and REGN?
Telix Pharmaceuticals' Accounts Receivable of A$194 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current Accounts Receivable is A$194 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (ASX:TLX) is currently considered Possible Value Trap. The stock's GF Value™ is A$45.04, compared to a current price of A$16.19 — trading 64.1% below its estimated fair value. The current Accounts Receivable is A$194 Mil. Telix Pharmaceuticals' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Telix Pharmaceuticals (ASX:TLX), the current Accounts Receivable is A$194 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (ASX:TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of A$16.19 is trading 64.1% below its estimated GF Value™ of A$45.04.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ASX:TLX:
Accounts Receivable: A$194 Mil
GF Value™: A$45.04 vs. price of A$16.19 (64.1% below fair value)
No single metric tells the full story. See the ASX:TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
59GF Score
Get the complete analysis for ASX:TLX
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TLX has been successfully added to your 
